Cargando…
Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide...
Autores principales: | Franses, Joseph W, Lim, Mir, Burgoyne, Adam M, Mody, Kabir, Lennerz, Jochen, Chang, Jeremy, Imperial, Robin, Dybel, Stacey N, Dinh, Thi M, Masannat, Jude, Weipert, Caroline M, Hsiehchen, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632309/ https://www.ncbi.nlm.nih.gov/pubmed/36103364 http://dx.doi.org/10.1093/oncolo/oyac189 |
Ejemplares similares
-
Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden
por: Franses, Joseph W., et al.
Publicado: (2021) -
Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma
por: Lim, Mir, et al.
Publicado: (2023) -
DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
por: Hsiehchen, David, et al.
Publicado: (2020) -
Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma
por: Wong, Mary, et al.
Publicado: (2021) -
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)